Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) EBITDA (2022 - 2025)

Summit Therapeutics' EBITDA history spans 4 years, with the latest figure at -$219.0 million for Q4 2025.

  • For Q4 2025, EBITDA fell 257.97% year-over-year to -$219.0 million; the TTM value through Dec 2025 reached -$1.1 billion, down 388.5%, while the annual FY2025 figure was -$1.1 billion, 388.28% down from the prior year.
  • EBITDA reached -$219.0 million in Q4 2025 per SMMT's latest filing, up from -$231.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$15.8 million in Q2 2023 to a low of -$565.9 million in Q2 2025.
  • Average EBITDA over 4 years is -$139.7 million, with a median of -$58.2 million recorded in 2024.
  • Peak YoY movement for EBITDA: skyrocketed 91.98% in 2024, then crashed 837.92% in 2025.
  • A 4-year view of EBITDA shows it stood at -$17.9 million in 2022, then plummeted by 104.93% to -$36.7 million in 2023, then tumbled by 66.74% to -$61.2 million in 2024, then crashed by 257.97% to -$219.0 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's EBITDA are -$219.0 million (Q4 2025), -$231.8 million (Q3 2025), and -$565.9 million (Q2 2025).